GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharnext SA (XPAR:ALPHA) » Definitions » Common Stock

Pharnext (XPAR:ALPHA) Common Stock : €0.18 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Pharnext Common Stock?

Pharnext's quarterly common stock increased from Dec. 2022 (€0.37 Mil) to Jun. 2023 (€0.50 Mil) but then declined from Jun. 2023 (€0.50 Mil) to Dec. 2023 (€0.18 Mil).

Pharnext's annual common stock declined from Dec. 2021 (€1.32 Mil) to Dec. 2022 (€0.37 Mil) and declined from Dec. 2022 (€0.37 Mil) to Dec. 2023 (€0.18 Mil).


Pharnext Common Stock Historical Data

The historical data trend for Pharnext's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharnext Common Stock Chart

Pharnext Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.19 1.32 0.37 0.18

Pharnext Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.32 0.22 0.37 0.50 0.18

Pharnext Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Pharnext (XPAR:ALPHA) Business Description

Traded in Other Exchanges
Address
11-13 Rue Rene Jacques, Issy-Les-Moulineaux, FRA, 92130
Pharnext SA is a biopharmaceutical company developing treatments targeting neurodegenerative diseases. The company also develop a Pleotherapy technology platform. Its product in the pipeline includes SYNGILITY; PXT3003 and PXT864. The company's only segment being research and development on new pharmaceutical therapies based on Pleotherapy.

Pharnext (XPAR:ALPHA) Headlines

No Headlines